Vanguard CPV-Lepto Suspensie voor injectie

Authorised

- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:
Vanguard CPV-Lepto Suspensie voor injectie
Vanguard CPV-Lepto Suspension injectable
Vanguard CPV-Lepto Injektionssuspension

Active substance:
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated

Canine parvovirus, strain NL-35-D, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
40.00 Hamster protective Dose 80 % (Ph. Eur. Monograph) / 1.00 millilitre(s)

Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
40.00 Hamster protective Dose 80 % (Ph. Eur. Monograph) / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live
10000000.00 cell culture infective dose 50 / 1.00 millilitre(s)

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AL04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Belgium

Available in:

Belgium

Package description:

Vanguard CPV-Lepto 25 Vials with 1 dose of Suspension for injection
Vanguard CPV-Lepto 100 Vials with 1 dose of Suspension for injection

Vanguard CPV-Lepto 10 Vials with 1 dose of Suspension for injection
Vanguard CPV-Lepto 1 Vial with 1 dose of Suspension for injection

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
30/03/1993

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V161551

Date of authorisation status change:
10/03/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
